Wockhardt locked its upper circuit limit at Rs. 333.70, up by 30.30 points or 9.99% from its previous closing of Rs. 303.40 on the BSE.
The scrip opened at Rs. 308.00 and has touched a high and low of Rs. 333.70 and Rs. 308.00 respectively. So far 782962 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 411.60 on 11-Feb-2020 and a 52 week low of Rs. 147.20 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 333.70 and Rs. 258.55 respectively. The current market cap of the company is Rs. 3695.23 crore.
The promoters holding in the company stood at 72.13%, while Institutions and Non-Institutions held 4.90% and 22.97% respectively.
Wockhardt has entered into an agreement with the UK Government to fill finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.
Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: